Healthcare / Health Information ServicesNasdaqGS
$15.80
+0.60 (+3.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-150.1M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.4%
↓Gross Margin
55.7%
↑Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
+20.0%
FCF CAGR
—
FCF margin
4.9%
FCF / Net income
-0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $255.9M · net income $-103.3M · FCF $12.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $255.9M | $255.9M | $207.5M | $216.7M | $181.0M | $137.9M | $108.1M | $85.5M |
| Net Income | $-103.3M | $-103.3M | $-187.1M | $40.7M | $-149.2M | $-100.4M | $-24.5M | $-24.6M |
| EBITDA | $-160.9M | $-160.9M | $-203.1M | $-171.9M | $-142.5M | $-108.6M | $-57.3M | $-35.1M |
| EPS | -1.41 | -1.41 | -2.57 | 0.54 | -2.10 | -1.42 | -0.41 | — |
| Gross Margin | 55.7% | 55.7% | 63.6% | 64.9% | 55.8% | 47.6% | 58.7% | 57.4% |
| Operating Margin | -65.2% | -65.2% | -100.8% | -81.9% | -81.1% | -80.8% | -56.4% | -45.3% |
| Net Margin | -40.4% | -40.4% | -90.2% | 18.8% | -82.4% | -72.8% | -22.6% | -28.7% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.30 | 0.30 | 0.28 | 0.23 | 0.26 | — | — | — |
| Current Ratio | 2.74 | 2.74 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $12.5M | $12.5M | $-164.7M | $-150.1M | $-127.7M | $-77.8M | $14.2M | $-27.9M |
| Returns | ||||||||
| ROE | -28.4% | -28.4% | -44.4% | 7.4% | -33.3% | -18.0% | -3.9% | 26.3% |
| Valuation | ||||||||
| P/E | — | — | — | 58.26 | — | — | — | — |
| P/B | 3.19 | 3.19 | 3.60 | 4.30 | 2.87 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | 23.3% | 23.3% | -4.2% | 19.7% | — | 27.6% | 26.4% | — |
| EPS Growth | 45.1% | 45.1% | -575.9% | 125.7% | — | -246.3% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.57 → -1.41
Residual
-26.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.